Skip to main content
ISOP ACoP 2025 Annual Conference Main banner

Xiang Gao, PhD (he/him/his)

VP, Head of Pharmacokinetics and Clinical Pharmacology
Ionis Pharmaceuticals
Vista, California, United States

Xiang Gao, Ph.D. is working at Ionis Pharmaceuticals as a Vice President, head of Pharmacokinetics and Clinical Pharmacology. He received a B.S. and M.S. in mechanical/chemical engineering from Beijing Institute of Technology (1983/1986), a M.S. in analytical chemistry from University of Toledo (1992), and a Ph.D in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University (1997). Prior to joining Ionis, Dr. Gao worked for Kira (1 year) as a Vice President, head of Translational Sciences, for Alexion (8 years) as an executive director, Pfizer (>9 years, 2004-2013) as a director and group head at clinical pharmacology, Bristol-Myers Squibb for 5 years (1999-2004) and MDS Harris for 2 years (1997-1999). He has published 44 peer-reviewed scientific manuscripts and more than 90 abstracts. During his tenure with pharmaceutical industry, he has contributed to 10 major NDA/BLA/MMA filings and approvals (Abilify for treatment of schizophrenia and Metaglip for treatment of diabetes 2, Xiapex for Treatment of Duputran, Revatio for Pediatric indication), Soliris for the treatment of aHUS/MG/NMOSD, Ultomiris for PNH/aHUS, Asfotase Alfa for the treatment of HPP, Wainua for the treatment of adults with hATTR-PN, Olezarsen for FCS, Donidalosen for HAE, and numerious supplemental NDA filings, IND applications. He has extensive experience spreading from preclinical PK ADME, to clinical PK, drug-drug interaction, PK-PD modeling and simulation, and worked on variety of disease areas such as CNS, CVMED, inflammation and immunology, infectious disease, hematology, and rare diseases etc. His current role at Ionis includes serving as a head of PK/CP department overseeing DMPK, Bioanalytical, PK operations, Clinical Pharmacology, and Pharmacometrics. He is very passionate for implementing and advocating the model informed drug discovery development paradigm using integrated quantitative approaches and quantitative system pharmacology.

Disclosure information not submitted.

Presentation(s):

Email Xiang